Typical Atrial Flutter Clinical Trial
— FLUTTEROfficial title:
Fluoroscopic, Contact Force and Local Impedance With Ultra-high Density Mapping Guided Radiofrequency Ablation Comparison for cavoTricuspid Isthmus dependenT Atrial fluttER: the FLUTTER Study
NCT number | NCT04434599 |
Other study ID # | 281105 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | October 30, 2022 |
Est. completion date | January 1, 2024 |
Verified date | October 2023 |
Source | University of Manchester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Catheter ablation is a first-line treatment for patients with cavotricuspid isthmus (CTI) dependent atrial flutter (AFL; also known as typical AFL), a common arrhythmia. This is done using radiofrequency (RF) catheters and single-procedure success is approximately 95%. Ablation is often done using one of three methods: 1. fluoroscopically, using X-rays to guide the operator to visualise catheter position within the heart. This method involves the most radiation exposure to patient and operator. Ablation is generally performed for a set time-period (eg. 30-60secs) to ensure each ablation lesion is successful. 2. using a 3-dimensional mapping system which allows the catheters to be magnetically located and visualised on a monitor without X-rays, and using "contact force" (CF) sensing catheters. This requires minimal X-ray use, and by ensuring a minimum degree of force between catheter tip and the heart before applying RF for a set time-period (eg. 30 seconds), operators can be more confident of successful lesions. 3. using an ultra-high density mapping system which uses magnetic tracking as above, but allows higher resolution visualisation of the cardiac electrical system with potential for improving procedure success; this has not yet been formally evaluated for AFL. Catheters using this method use "local impedance" (LI) instead of CF. This is a direct measure of heart tissue impedance with real-time changes during ablation. A minimum drop or plateau in the LI value during ablation allows confidence of lesion success, without the need to ablate for a pre-defined time-period. This could potentially reduce ablation time and subsequent complications, but has also not yet been formally compared to the above for this indication. This prospective randomised study aims to compare these three standard of care procedures to determine if differences in ablation metrics, efficacy and safety exist.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 1, 2024 |
Est. primary completion date | September 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients under the care of the NHS - Aged 18-80 years - Symptoms and 12-lead ECG suggestive of typical (cavotricuspid isthmus dependent) atrial flutter - Due to undergo first-time cavotricuspid isthmus ablation (including as part of a combined ablation if also having pulmonary vein isolation for atrial fibrillation) on clinical grounds Exclusion Criteria: Pre-procedure: - Inability to given informed consent / lack of mental capacity - Obesity (BMI >40) - Congenital heart disease or tricuspid valve abnormalities likely to prolong procedure time, including Ebstein anomaly, atrial septal defects, tricuspid valve repair or replacement, severe tricuspid valve regurgitation - Inability or unwillingness to receive oral anticoagulation with a vitamin K antagonist (VKA) or non-VKA oral anticoagulant (NOAC) - Previous cavotricuspid isthmus ablation procedure - Known infiltrative cardiomyopathy - Pregnancy - Age < 18 or >80 - Inability to speak adequate English/need for an interpreter for study consent process Post procedure: - arrhythmia mechanism found not to be cavotricuspid isthmus dependent atrial flutter |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Manchester | Manchester University NHS Foundation Trust |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from first application of radiofrequency energy to confirmation of bidirectional cavotricuspid isthmus block | Time from first application of radiofrequency energy to confirmation of bidirectional cavotricuspid isthmus block | At time of procedure | |
Secondary | Mean total ablation time to achieve bidirectional cavotricuspid isthmus block | Mean total ablation time to achieve bidirectional cavotricuspid isthmus block | At time of procedure | |
Secondary | Mean total radiation exposure | Mean total radiation exposure | At time of procedure | |
Secondary | Mean total number of ablation lesions required to achieve bidirectional cavotricuspid isthmus block | Mean total number of ablation lesions required to achieve bidirectional cavotricuspid isthmus block | At time of procedure | |
Secondary | Number of cases where bidirectional cavotricuspid isthmus block was not achieved after the first pass of ablation | Number of cases where bidirectional cavotricuspid isthmus block was not achieved after the first pass of ablation | At time of procedure | |
Secondary | Mean time taken for second pass ablation (with or without the use of 3D mapping) to achieve bidirectional cavotricuspid isthmus block | Mean time taken for second pass ablation (with or without the use of 3D mapping) to achieve bidirectional cavotricuspid isthmus block | At time of procedure | |
Secondary | Locations of breakthrough across the initial ablation line | Locations of breakthrough across the initial ablation line | At time of procedure | |
Secondary | Frequency of procedural complications | Frequency of procedural complications | At time of and immediately following procedure | |
Secondary | Acute and medium-term success rates | Acute and medium-term success rates | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05777850 -
High-Power Short-Duration Radiofrequency Ablation in Patients With Typical Atrial Flutter
|
N/A | |
Completed |
NCT01401361 -
Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System
|
Phase 3 | |
Completed |
NCT00984204 -
Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)
|
Phase 3 | |
Withdrawn |
NCT01710150 -
Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter
|
N/A | |
Completed |
NCT01408485 -
Therapy™ Cool Flex™ Irrigated Ablation System for Typical Atrial Flutter
|
N/A | |
Completed |
NCT04658940 -
AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter)
|
N/A | |
Recruiting |
NCT00750711 -
Typical Flutter Ablation:A Comparison of 4 mm Versus 2 mm Irrigated cathéters
|
N/A | |
Recruiting |
NCT03867266 -
Typical Atrial Flutter, Ablation Index and Point by Point Ablation
|
||
Not yet recruiting |
NCT06157437 -
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Typical Atrial Flutter
|
N/A | |
Recruiting |
NCT04657055 -
AcQBlate Force Sensing Ablation System EU Study for Atrial Flutter (AcQForce Flutter-EU)
|
N/A |